Use of nebivolol as an anti-atherogenic

Details Use of nebivolol as an anti-atherogenic Use of nebivolol as an anti-atherogenic

1998-12-21

2000-06-13

Criares, Theodore J.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A01M 4316

Patent

active

060750464

ABSTRACT:
This invention relates to the use of an .alpha.,.alpha.'-iminobis(methylene)bis[2-chromanmethanol] derivative for the manufacture of a medicament for the therapeutic or prophylactic treatment of humans suffering from or prone to degenerative diseases and conditions of the vascular and nervous system which are associated with oxidative stress.

REFERENCES:
patent: 5759580 (1998-06-01), Jans et al.
patent: 5874461 (1999-02-01), Courcelles et al.
G. Vandeplassche et al., "Cytoprotective Effects of Nebivolol", Drug Investigation, vol. 3 (Suppl.1):134-136, 1991.
L.M.A.B. Van Bortel et al. Antihypertensive treatment and vessel wall properties of large arteries, Besic Res. Cardiol, vol. 86, Suppl. 1, pp. 91-95, 1991.
Salvetti et al, "What effect Doe Blood Pressure Control Have on the Progression Towards Renal Failure?", American Journal of Kidney Diseases, vol. 21, No. 6, Suppl. 3, Jun. 1993, pp. 10-15.
P.M. Vanhoutte, "Endothelium, B -Blockers and Vascular Protection", Drug Investigation 3 (Suppl.1): 201-203, 1991.

Affiliated with

Also associated with

Rating

Use of nebivolol as an anti-atherogenic does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of nebivolol as an anti-atherogenic, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of nebivolol as an anti-atherogenic will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2069013